Regulus Therapeutics (RGLS) Tops Q4 EPS by 11c
Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $5.09 million.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.